

UBS ETC

Linked to UBS Customised Strategy Basket on White Sugar Futures Issued by UBS AG, London Branch

Cash settled

SVSP/EUSIPA Product Type: Tracker Certificate (1300, Callable, Putable)

Valor: 23554624

Final Terms

This Product does not represent a participation in any of the collective investment schemes pursuant to Art. 7 ff of the Swiss Federal Act on Collective Investment Schemes (CISA) and thus does not require an authorisation of the Swiss Financial Market Supervisory Authority (FINMA). Therefore, investors in this Product are not eligible for the specific investor protection under the CISA (this paragraph is relevant to public offerings in Switzerland only).

1. Description of the Product

About UBS ETCs

UBS Exchange Traded Commodities (ETCs) are simple and efficient products for investors in commodity markets. They provide exposure to commodities by tracking their performance on a 1:1 basis, less management fees. UBS ETCs offer cost efficiency, open-ended tracking and daily exchange liquidity.

Information on Underlying

Underlying(s)	Initial Strategy Basket Level	Conversion Ratio
UBS Customised Strategy Basket on White Sugar Futures (the "Strategy Basket")	84.2102	1:1 (1 Unit refers to 1 Underlying)

See Annex **Strategy Basket Description**

Product Details

Security Numbers Valor: 23554624 / ISIN: CH0235546246 / WKN: US22UE

Issue Size Up to 1'000'000 Units (with reopening clause)

Issue Price USD 84.2102 (unit quotation)

Management Fee (MF_t) 0.00% p.a. (subject to adjustment)

Settlement Currency USD

Dates

30 January 2014 Launch Date Pricing Date ("Pricing") 30 January 2014 First Trading Date 06 February 2014 Issue Date / Payment Date 06 February 2014 Expiration Date ("Expiry") Open End

Contact: UBS AG, P.O. Box, 8098 Zürich Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com

www.ubs.com/keyinvest Product Hotline: +41-44-239 76 76*

Investors outside of Switzerland should consult their local client advisors

Maturity Date / Redemption

Date

Means the 3rd Business Day following the Effective Exercise Date. In case this date is not a Business Day the next following Business Day will apply

(subject to Market Disruption Event provisions).

Redemption

The Investor is entitled to receive from the Issuer on the Redemption Date an amount in the Settlement Currency, according to the following formula and taking into account the Conversion Ratio:

Expiration Value – MF_t

Management Fee (MF_t) The level of the Management Fee, if any, on day t after the Pricing Date. The

Management Fee will be determined at the reasonable discretion of the Calculation Agent and as per provisions set out under Management Fee.

Expiration Value Closing price of the component(s) of the Underlying Strategy Basket on the Effective

Exercise Day, as reasonably determined by the Calculation Agent.

Product Structure

With an UBS-ETC the Investor can participate in the performance of the Underlying Strategy Basket. The downside risk is similar to that of the Strategy Basket, i.e. the Investor could lose his total investment if the Underlying Strategy Basket value falls to zero. UBS-ETCs are products for Investors who expect the Underlying Strategy Basket to increase in value. The terms of the Product may be subject to adjustments during its lifetime. Detailed information on such adjustments is to be found in the General Terms and Conditions for Structured Products on Equity, Commodity and Index Underlyings.

General Information

Issuer UBS AG, London Branch
Issuer Rating A2 Moody's / A S&P's / A Fitch

Lead Manager UBS AG, Zurich (UBS Investment Bank)

Calculation Agent UBS AG, London Branch

Paying Agent UBS AG, Zurich

Listing Vienna Stock Exchange, will be applied for

Related Exchange The exchanges on which components comprising the Strategy Basket are traded,

as determined by the Calculation Agent.

Secondary Market Daily price indications will be available on Reuters/Bloomberg,

www.ubs.com/keyinvest and Telekurs from 09:15-17:15 CET (see also section

'Secondary Market Provisions").

Minimum Investment 1 Unit(s) (subject to Selling Restrictions)

Minimum Trading Lot 1 Unit(s)

Clearing SIX SIS, Euroclear, Clearstream (registered as intermediated securities with SIX SIS

AG, in Switzerland)

Form of deed Uncertificated securities

Governing Law / Jurisdiction Swiss / Zurich

Product One USD-denominated UBS-ETC unit is equivalent to one (1) "Product". "Products"

wherever used herein shall be construed to mean integral multiples of the same,

subject to the issue size.

Management Fee Adjustment The Issuer has the annual right, on 28 May, for the first time on 28 May 2014

("Fee Adjustment Notice Date") to adjust the Management Fee effective 12 months after the Fee Adjustment Notice Date by publish a notice to that effect (in case that any of the dates is not an Exchange Business Day, the next following

Exchange Business Day applies).

Management Fee Adjustment

Date

Means the day when the Management Fee Adjustment becomes effective (corresponds to 12 months after the Fee Adjustment Notice Date, subject to

Market Disruption Event provisions).

Contact: UBS AG, P.O. Box, 8098 Zürich Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com

Internet: www.ubs.com/keyinvest Product Hotline: +41-44-239 76 76

Investors outside of Switzerland should consult their local client advisors.

Issuer Call Right	The Issuer has a right to call on any Exchange Business Day the UBS-ETC for early redemption by giving notice to that effect by communicating the termination date (the "Termination Date"). The termination becomes effective as of close of business of the Termination Date, for a value equal to Redemption (as described herein) on the Termination Date (in case that any of the dates is not a Business Day, the next following Business Day applies). Subject to Market Disruption Event provisions the UBS-ETC will be redeemed on the Redemption Date.
Investor Exercise Right	In addition to the possibility to sell the UBS-ETC at any time in the Secondary Market (subject to market conditions), each Investor has a right to exercise on any Exchange Business Day (the "Exercise Date") the UBS-ETC (notice to be received not later than 10 am CET on the relevant Exercise Date) for a value equal to Redemption (as described herein) on the Exercise Date minus an early termination fee of up to 2% of the Expiration Value (as determined in the sole discretion of the Calculation Agent). The exercise will become effective as of close of business on the Exercise Date. Subject to Market Disruption Event provisions the UBS-ETC will be redeemed on the Redemption Date.
Effective Exercise Date	Means the day when either the Issuer's Call Right or the Investor's Exercise Right becomes effective.
Exchange Business Day	Means any Trading Day on which the closing prices of the Strategy Basket components are published by the Related Exchange.

Tax Treatment Switzerland

Swiss Federal Stamp Duty	Secondary market transactions are not subject to Swiss Stamp Duty.
Swiss Federal Income Tax	The transaction is subject to neither Swiss federal nor cantonal and communal Income Tax.
Swiss Withholding Tax	The product is not subject to the Swiss withholding tax.
EU Savings Tax Treatment	For Swiss paying agents, the product is not subject to the EU Savings tax (TK14).
Bilateral Agreements Switzerland – UK and Austria	For paying agents in Switzerland, the product is subject to the bilateral agreement on cooperation in the area of taxation of Switzerland with the United Kingdom or with Austria if it is held directly or indirectly by a relevant person resident in the United Kingdom or in Austria.

The tax information only provides a general overview over the Swiss tax consequences linked to this product based on the tax laws and the practice of the tax administration at the time of issue. Tax laws and the practice of tax administrations may change, possibly with retroactive effect.

Contact: UBS AG, P.O. Box, 8098 Zürich

Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com

Internet: www.ubs.com/keyinvest Product Hotline: +41-44-239 76 76*

Investors outside of Switzerland should consult their local client advisors.

Product Documentation

The Final Terms together with the 'General Terms and Conditions for Structured Products on Equity, Commodity and Index Underlyings', as amended from time to time ("General Terms and Conditions") shall form the entire documentation for this Product ("Product Documentation"), and accordingly the Final Terms should always be read together with the General Terms and Conditions. Definitions used in the Final Terms, but not defined therein shall have the meaning given to them in the General Terms and Conditions. Furthermore, the Final Terms shall serve as and fulfil the requirements of a 'Simplified Prospectus' in accordance with Art. 5 of the Swiss Federal Act on Collective Investment Schemes (CISA). In the event that the Product is listed (see above item 'Listing' under 'General Information'), the Product Documentation will be amended in accordance with the listing requirements of the relevant

During the whole term of this Product, the Product Documentation can be ordered free of charge from the Lead Manager at P.O. Box, CH-8098 Zurich (Switzerland), via telephone (+41-(0)44-239 47 03), fax (+41-(0)44-239 69 14) or via e-mail (swiss-prospectus@ubs.com). In addition, for clients outside of the United Kingdom, the Product Documentation is available on the internet at www.ubs.com/keyinvest.

Notices in connection with this Product shall be validly given by publication in electronic media such as Reuters and/or Telekurs. In addition, any changes with regard to the terms of this Product shall be published on the internet at www.ubs.com/keyinvest.

Classification

This Product does not represent a participation in any of the collective investment schemes pursuant to Art. 7 ff of the Swiss Federal Act on Collective Investment Schemes (CISA) and thus does not require an authorisation of the Swiss Financial Market Supervisory Authority (FINMA). Therefore, investors in this Product are not eligible for the specific investor protection under the CISA (this paragraph is relevant to public offerings in Switzerland only).

Furthermore, this Product does not benefit from any depositor protection under Art. 37b under the Swiss Federal Law on Banks and Savings Banks (Banking Act) or other forms of deposit insurance under any other law as might be applicable to this Product.

Prudential Supervision

UBS AG is authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA). In addition, its London Branch is authorised by the Prudential Regulation Authority and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority and its Jersey Branch is authorised and regulated by the Jersey Financial Services Commission (JFSC).

2. Prospects of Profits and Losses

Market Expectation The UBS-ETC is a product for Investors who expect the Underlying to increase over

the life of the Product.

Investors in this product should be experienced investors and familiar with both Risk Tolerance

derivative products and the commodity markets.

The Investors must be willing to make an investment that is exposed to the full

down-side risk of the Underlying.

The Investors do not require capital protection.

Profit Potential The product allows full participation in the positive performance of the Underlying.

Loss Potential The Investors may lose some or all of the investment as they are fully exposed to

the performance of the Underlying.

The Issuer is entitled to call the Product on any Exchange Business Day by

communicating the termination date.

UBS AG, P.O. Box, 8098 Zürich Private Investors: Please contact your client advisor or send an email to kevinvest@ubs.com Contact:

www.ubs.com/kevinvest Product Hotline: +41-44-239 76 76* Internet:

Investors outside of Switzerland should consult their local client advisors

3. Significant Risks for Investors

For product specific risks please see above (2. Prospects of Profits and Losses)

Risk Factors relating to the Issuer

In addition to the market risk with regard to the development of the Underlying, each Investor bears the general risk that the financial situation of the Issuer could deteriorate. The Products constitute immediate, unsecured and unsubordinated obligations of the Issuer, which, particularly in case of insolvency of the Issuer, rank pari passu with each and all other current and future unsecured and unsubordinated obligations of the Issuer, with the exception of those that have priority due to mandatory statutory provisions. The general assessment of the Issuer's creditworthiness may affect the value of the Products. This assessment generally depends on the ratings assigned to the Issuer or its affiliated companies by rating agencies such as Moody's, Fitch and Standard & Poor's.

The Issuer Ratings indicated in this document reflect the situation at the time of issuance and may be subject to changes. The actual Issuer Ratings at any given time can be seen on the Issuer's website (www.ubs.com) under "Analysts & Investors".

Secondary Market

The Issuer or the Lead Manager, as applicable, commits, under normal market conditions, to provide bid and offer prices for this Product on a regular basis and ensures liquidity in the secondary market. However, in case of market disruption events, any other unforeseen extraordinary events or force majeure, the Issuer or the Lead Manager, as applicable, makes no firm commitment to provide liquidity by means of bid and offer prices for this Product, and assumes no legal obligation to quote any such prices or with respect to the level or determination of such prices.

In special market situations, where the Issuer is completely unable to enter into hedging transactions, or where such transactions are very difficult to enter into, the spread between the bid and offer prices may be temporarily expanded, in order to limit the economic risks of the Issuer.

Market Risk

The investor is exposed to market disruption events (such as trading disruption, exchange disruption and early closure of the relevant exchange), adjustments and early termination which could have an impact on the redemption amount through delay in payment or change in value. For a detailed description of such events and their effects please read the Product Documentation.

Contact: UBS AG, P.O. Box, 8098 Zürich Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com

Internet: www.ubs.com/keyinvest Product Hotline: +41-44-239 76 76*

Investors outside of Switzerland should consult their local client advisors.

Important Information

This information is communicated by UBS AG and/or its affiliates ("UBS"). UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the transaction to which this document relates. UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this document. UBS' trading and/or hedging activities related to this transaction may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier is crossed. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available.

In certain circumstances UBS sells this Product to dealers and other financial institutions at a discount to the issue price or rebates to them for their account some proportion of the issue price. Further information is available on request.

Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in any transaction.

This document should not be construed as an offer, personal recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. The terms of any investment will be exclusively subject to the detailed provisions, including risk considerations, contained in the Information Memorandum, Prospectus or other issuer documentation for the issue of the Products/Notes (the "Prospectus").

UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS' prior written permission.

No action has been or will be taken in any jurisdiction that would permit a public offering of the Products described herein, save where explicitly stated in the Product Documentation. The Products must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold.

There is a possibility that costs, including taxes, related to transactions in connection with this Product may arise for the Investor that are not paid by UBS or imposed by it.

Contact: UBS AG, P.O. Box, 8098 Zürich Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com

Internet: www.ubs.com/keyinvest Product Hotline: +41-44-239 76 76

Selling Restrictions

Any Products purchased by any person for resale may not be offered in any jurisdiction in circumstances which would result in the Issuer being obliged to register any further documentation relating to this Product in such jurisdiction.

The restrictions listed below must not be taken as definitive guidance as to whether this Product can be sold in a jurisdiction. Additional restrictions on offering, selling or holding of this Product may apply in other jurisdictions. Investors in this Product should seek specific advice before on-selling this Product.

Europe - Any public offer of this Product within a EEA jurisdiction (EU member states plus Norway, Iceland and Liechtenstein) shall only be possible if compliant with the requirements of the EUPD and with the law of that jurisdiction

If the prospectus either does not qualify as a prospectus published in accordance with the requirements of the EUPD or is not filed with or notified to the relevant Financial Supervisory Authority, this Product may not be offered or sold in EEA jurisdictions other than 1) in minimum denominations of, or total consideration per investor of at least, EUR 50,000 (or equivalent in other currencies), provided that the offer is only being made in one or more EEA jurisdiction that will not, before the end of the offer period for the Notes, have implemented the provision under the Directive 2010/73/EU (the "PD Amending Directive") that increases this minimum denomination (or total consideration per investor) to EUR 100,000; or 2) only to Qualified Investors; and/or (aggregated for all distributors) to less than 100 or, if the relevant EEA jurisdiction has implemented the relevant provision of the 2010 PD Amending Directive, 150 natural or legal persons that are not Qualified Investors per EEA jurisdiction. "Qualified Investors" are persons or entities as defined in the Prospectus Directive.

For information on public offering in EEA jurisdictions please see under section "General Information" above.

Hong Kong – Each purchaser has represented and agreed that it has not issued or had in its possession for the purposes of issue, and will not issue or have in its possession for the purposes of issue, whether in Hong Kong or elsewhere, any advertisement, invitation or document relating to the Products, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to Products which are or are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance.

This is a structured product which involves derivatives. Do not invest in it unless you fully understand and are willing to assume the risks associated with it. If you are in any doubt about the risks involved in the product, you may clarify with the intermediary or seek independent professional advice.

Singapore - This document has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this document and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of this Product may not be circulated or distributed, nor may this Product be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act Chapter 289 of Singapore (the "SFA"), (ii) to a relevant person pursuant to Section 275(1), or any person pursuant to Section 275(1A), and in accordance with the conditions specified in Section 275, of the SFA or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

Where this Product is subscribed or purchased under Section 275 of the SFA by a relevant person which is:

- a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or
- a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor.

securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the securities pursuant of an offer made under Section 275 of the SFA except:

- to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any person arising from an offer referred to in Section 275(1A) or Section 276 (4)(i)(B) of the SFA; where no consideration is or will be given for the transfer; where the transfer is by operation of law; or as specified in Section 276 (7) of the SFA; or
- (2)
- (3)
- (4)
- as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore.

UK – For the purpose of non-discretionary accounts, this Product should not be sold with a consideration of less than 100,000 EUR or equivalent.

USA - This Product may not be sold or offered within the United States or to U.S. persons

UBS AG, P.O. Box, 8098 Zürich Private Investors: Please contact your client advisor or send an email to kevinvest@ubs.com Contact:

www.ubs.com/kevinvest Product Hotline: +41-44-239 76 76* Internet:

Investors outside of Switzerland should consult their local client advisors

Annex

Strategy Basket Description

The UBS Customised Strategy Basket on White Sugar Futures (the 'Strategy Basket') measures the uncollateralized returns from a basket of White Sugar Future contracts from LIF-NYSE Liffe – London (the 'Applicable Underlying'), rolled in accordance with the methodology of the Dow Jones-UBS Commodity IndexSM with the following adjustments:

- A Commodity Index Multiplier of 1 is applied
- The Lead month in each roll period is provided by the roll schedule below

Dates:	01. Jan	01. Feb	01. Mar	01. Apr	01. May	01. Jun	
Future contract:	March	March	May	May	August	August	
Dates:	01. Jul	01. Aug	01. Sep	01. Oct	01. Nov	01. Dec	
Future contract:	October	October	October	December	December	March	

The Dow Jones-UBS Commodity IndexSM Methodology can be downloaded on www.djindexes.com/commodity/?go=handbook

Contact: UBS AG, P.O. Box, 8098 Zürich Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com

Internet: www.ubs.com/keyinvest Product Hotline: +41-44-239 76 76*

Investors outside of Switzerland should consult their local client advisors.